Green Biologics' IPO on the Shenzhen Stock Exchange has been terminated. It is one of the well-known companies in the domestic flavor and fragrance industry.

On September 3, Green Biological Technology Co., Ltd. (referred to as Green Biotech) terminated its IPO on the ChiNext board of the Shenzhen Stock Exchange. This was due to Green Biotech and the sponsor withdrawing their application for listing. According to Article 62 of the Shenzhen Stock Exchange Rules Governing the Review of Stock Issuance and Listing (Revised in 2024), the Shenzhen Stock Exchange decided to terminate the review of its IPO. The prospectus shows that since its establishment, Green Biotech has been focusing on the research, production, and sales of flavor products, forming three product series: pine oil, cypress oil, and synthetic flavors. Specific products mainly include sandalwood series, methyl cypress ketone, turkisol series, and nearly 40 other detailed varieties, mainly used as raw materials for formulating daily chemical fragrances. Green Biotech is a pioneer and important enterprise in China's flavor industry. After more than 20 years of development and accumulation, it has formed core competitiveness in the research and production of high-quality flavors. The company is one of the few flavor enterprises in China that has mastered the production technology of turkisol and realized industrialization. It is also one of the largest suppliers of methyl cypress ketone and an important supplier of sandalwood products in China. It is also a well-known enterprise in China's flavor and fragrance industry. In addition, Green Biotech is one of the first flavor enterprises in China to enter the international flavor market. It is the global leading registrant of five products including methyl cypress ketone, ethyl cypress ester, dimethyl heptanol, dihydrocoumarin, and cypress camphor under the REACH regulation. It has successfully entered the global supply chain systems of international famous flavor and fragrance companies such as Givaudan, Firmenich, IFF, Symrise, and P&G, as well as global daily chemical companies, establishing stable cooperation relationships with them. After deducting issuance expenses, the raised funds will be invested in the following projects in order of priority. Financially, in 2021, 2022, and 2023, Green Biotech achieved revenues of approximately RMB 594 million, RMB 631 million, and RMB 735 million respectively. During the same periods, the net profits were approximately RMB 40.74 million, RMB 68.14 million, and RMB 92.92 million respectively.